{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:44:36Z","timestamp":1776692676324,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00120-024-02473-6","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:11:48Z","timestamp":1732637508000},"page":"1240-1245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Das nicht-klarzellige Nierenzellkarzinom","Non-clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"63","author":[{"given":"Marit","family":"Ahrens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"5","key":"2473_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch\u00a0H, Amin\u00a0MB, Berney\u00a0DM et\u00a0al (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A:\u00a0Renal, Penile, and Testicular Tumours. Eur Urol 82(5):458\u2013468 (Nov)","journal-title":"Eur Urol"},{"issue":"11","key":"2473_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14737140.2021.1959319","volume":"21","author":"L Bergmann","year":"2021","unstructured":"Bergmann\u00a0L, Weber\u00a0S, Hartmann\u00a0A, Ahrens\u00a0M (2021) Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther 21(11):1273\u20131286 (Nov)","journal-title":"Expert Rev Anticancer Ther"},{"key":"2473_CR3","series-title":"version","volume-title":"NCCN Clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer","author":"RJ Motzer","year":"2024","unstructured":"Motzer\u00a0RJ, Jonasch\u00a0E, Agarwal\u00a0N et\u00a0al (2024) NCCN Clinical practice guidelines in oncology (NCCN guidelines): Kidney cancer. version, Bd. 4"},{"key":"2473_CR4","unstructured":"S3-Leitlinie Nierenzellkarzinome, Version 5.01 \u2013 Juli 2024 AWMF-Registernummer: 043-017OL"},{"key":"2473_CR5","unstructured":"https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/nierenzellkarzinom-hypernephrom\/@guideline\/html\/index.html"},{"issue":"8","key":"2473_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Tomczak\u00a0P, Park\u00a0SH (2021) KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N\u00a0Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"issue":"8","key":"2473_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf\u00a0ME, Kim\u00a0SE, Master\u00a0V (2024) et\u00a0al.s NB, Carducci MA. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase\u00a03\u00a0study. Lancet Oncol 25(8):1038\u20131052 (Aug)","journal-title":"Lancet Oncol"},{"issue":"106482","key":"2473_CR8","first-page":"10","volume":"108","author":"B Oza","year":"2021","unstructured":"Oza\u00a0B, Frangou\u00a0E, Smith\u00a0B et\u00a0al (2021) RAMPART: A\u00a0phase\u00a0III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials 108(106482):10\u201310","journal-title":"Contemp Clin Trials"},{"issue":"10379","key":"2473_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer\u00a0RJ, Russo\u00a0P, Gr\u00fcnwald\u00a0V, Tomita\u00a0Y, Zurawski\u00a0B, Parikh\u00a0O, Buti\u00a0S, Barth\u00e9l\u00e9my\u00a0P, Goh\u00a0JC, Ye\u00a0D, Lingua\u00a0A, Lattouf\u00a0JB, Albig\u00e8s\u00a0L, George\u00a0S, Shuch\u00a0B, Sosman\u00a0J, Staehler\u00a0M, V\u00e1zquez Est\u00e9vez\u00a0S, Simsek\u00a0B, Spiridigliozzi\u00a0J, Chudnovsky\u00a0A, Bex\u00a0A (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a\u00a0double-blind, randomised, phase\u00a03\u00a0trial. Lancet 401(10379):821\u2013832","journal-title":"Lancet"},{"issue":"5","key":"2473_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/bju.15981","volume":"131","author":"C Riveros","year":"2023","unstructured":"Riveros\u00a0C, Huang\u00a0E, Ranganathan\u00a0S et\u00a0al (2023) Adjuvant immunotherapy in renal cell carcinoma: a\u00a0systematic review and meta-analysis. BJU Int 131(5):553\u2013561 (May)","journal-title":"BJU Int"},{"key":"2473_CR11","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer\u00a0RJ, Bacik\u00a0J, Mariani\u00a0T et\u00a0al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J\u00a0Clin Oncol 20:2376\u20132381","journal-title":"J Clin Oncol"},{"key":"2473_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fern\u00e1ndez-Pello","year":"2017","unstructured":"Fern\u00e1ndez-Pello\u00a0S, Hofmann\u00a0F, Tahbaz\u00a0R et\u00a0al (2017) A\u00a0systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71:426\u2013436","journal-title":"Eur Urol"},{"key":"2473_CR13","doi-asserted-by":"crossref","unstructured":"Bergmann L, Ahrens M, Albiges L et\u00a0al (2024) Prospective randomised phase-II trial of Ipilimumab\/Nivolumab versus standard of care in non-clear cell renal cell cancer\u2014results of the SUNNIFORECAST trial. ESMO: LBA75","DOI":"10.1016\/j.annonc.2024.08.2318"},{"key":"2473_CR14","doi-asserted-by":"crossref","unstructured":"Powles T, Albiges L, Bex A et\u00a0al (2024) Renal cell carinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"2473_CR15","unstructured":"https:\/\/www.nccn.org\/guidelines\/category_1"},{"issue":"5","key":"2473_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/PPO.0000000000000477","volume":"26","author":"P Ravi","year":"2020","unstructured":"Ravi\u00a0P, Bakouny\u00a0Z, Schmidt\u00a0A et\u00a0al (2020) Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. Cancer\u00a0J 26(5):464\u2013470","journal-title":"Cancer J"},{"issue":"2","key":"2473_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","volume":"26","author":"JP Dutcher","year":"2009","unstructured":"Dutcher\u00a0JP, de Souza\u00a0P, McDermott\u00a0D et\u00a0al (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202\u2013209","journal-title":"Med Oncol"},{"key":"2473_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","volume":"69","author":"NM Tannir","year":"2016","unstructured":"Tannir\u00a0NM, Jonasch\u00a0E, Albiges\u00a0L et\u00a0al (2016) Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A\u00a0Randomized Multicenter Phase\u00a02 Trial. Eur Urol 69:866\u2013874","journal-title":"Eur Urol"},{"key":"2473_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","volume":"17","author":"AJ Armstrong","year":"2016","unstructured":"Armstrong\u00a0AJ, Halabi\u00a0S, Eisen\u00a0T et\u00a0al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a\u00a0multicentre, open-label, randomised phase\u00a02\u00a0trial. Lancet Oncol 17:378\u2013388","journal-title":"Lancet Oncol"},{"issue":"7\u20138","key":"2473_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000508450","volume":"43","author":"L Bergmann","year":"2020","unstructured":"Bergmann\u00a0L, Gr\u00fcnwald\u00a0V, Maute\u00a0L et\u00a0al (2020) A\u00a0Randomized Phase\u00a0IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncol Res Treat 43(7\u20138):333\u2013339","journal-title":"Oncol Res Treat"},{"issue":"4","key":"2473_CR21","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/j.clgc.2016.12.024","volume":"15","author":"S Buti","year":"2017","unstructured":"Buti\u00a0S, Bersanelli\u00a0M, Maines\u00a0F et\u00a0al (2017) First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clin Genitourin Cancer 15(4):e609\u2013e614","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"2473_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1200\/JCO.2020.38.6_suppl.685","volume":"38","author":"TE Hutson","year":"2020","unstructured":"Hutson\u00a0TE, Michaelson\u00a0MD, Kuzel\u00a0TM et\u00a0al (2020) A\u00a0phase\u00a0II study of lenvatinib plus everolimus in patients with advanced non clear cell renal cell carcinoma (nccRCC). J\u00a0Clin Oncol 38(6):685","journal-title":"J Clin Oncol"},{"issue":"4","key":"2473_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","volume":"20","author":"N Mart\u00ednez Chanz\u00e1","year":"2019","unstructured":"Mart\u00ednez Chanz\u00e1\u00a0N, Xie\u00a0W, Bilen\u00a0AM et\u00a0al (2019) Cabozantinib in advanced non-clear-cell renal cell carcinoma: a\u00a0multicentre, retrospective, cohort study. Lancet Oncol 20(4):581\u2013590","journal-title":"Lancet Oncol"},{"issue":"8","key":"2473_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","volume":"6","author":"TK Choueiri","year":"2020","unstructured":"Choueiri\u00a0TK, Heng\u00a0DYC, Lee\u00a0JL et\u00a0al (2020) Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase\u00a03 Randomized Clinical Trial. JAMA Oncol 6(8):1247\u20131255","journal-title":"JAMA Oncol"},{"issue":"10275","key":"2473_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","volume":"397","author":"SK Pal","year":"2021","unstructured":"Pal\u00a0SK, Tangen\u00a0C, Thompson\u00a0IM Jr et\u00a0al (2021) A\u00a0comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet 397(10275):695\u2013703","journal-title":"Lancet"},{"key":"2473_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.eururo.2021.03.015","volume":"80","author":"TE Hutson","year":"2021","unstructured":"Hutson\u00a0TE, Michaelson\u00a0MD, Kuzel\u00a0TM et\u00a0al (2021) A\u00a0single-arm, Multicenter, Phase\u00a02 Study of Lenvatinib plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol 80:162\u2013170","journal-title":"Eur Urol"},{"issue":"21","key":"2473_CR27","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee\u00a0CH, Voss\u00a0MH, Carlo\u00a0MI et\u00a0al (2022) Phase\u00a0II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J\u00a0Clin Oncol 40(21):2333\u20132341","journal-title":"J Clin Oncol"},{"key":"2473_CR28","doi-asserted-by":"crossref","unstructured":"Fitzgerald KN, Lee CH, Voss MH et\u00a0al (2024) Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a\u00a0Phase\u00a02 Trial. Eur Urol 22: (S0302\u20132838(24)02349\u20132)","DOI":"10.1016\/j.eururo.2024.04.025"},{"issue":"8","key":"2473_CR29","doi-asserted-by":"publisher","first-page":"P881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges\u00a0L, Gurney\u00a0H, Atduev\u00a0V et\u00a0al (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet Oncol 24(8):P881\u2013891","journal-title":"Lancet Oncol"},{"issue":"2","key":"2473_CR30","doi-asserted-by":"publisher","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","volume":"10","author":"SS Tykodi","year":"2022","unstructured":"Tykodi\u00a0SS, Gordan\u00a0LN, Alter\u00a0RS et\u00a0al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase\u00a03b\/4 CheckMate 920 trial. J\u00a0Immunother Cancer 10(2):e3844","journal-title":"J Immunother Cancer"},{"key":"2473_CR31","doi-asserted-by":"publisher","first-page":"e004780","DOI":"10.1136\/jitc-2022-004780","volume":"11","author":"MB Atkins","year":"2023","unstructured":"Atkins\u00a0MB, Jegede\u00a0OA, Haas\u00a0NB et\u00a0al (2023) Phase\u00a0II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-na\u00efve patients with advanced non-clear cell renal cell carcinoma (HCRN H\u2019GU16-260-Cohort\u00a0B). J\u00a0Immunother Cancers 11:e4780","journal-title":"J Immunother Cancers"},{"key":"2473_CR32","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.22.01414","volume":"41","author":"C Suar\u00e9z","year":"2023","unstructured":"Suar\u00e9z\u00a0C, Larkin\u00a0J, Patel\u00a0PM et\u00a0al (2023) Phase\u00a0II study investigation the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J\u00a0Clin Oncol 41:2493\u20132502","journal-title":"J Clin Oncol"},{"key":"2473_CR33","doi-asserted-by":"publisher","first-page":"e005445","DOI":"10.1136\/jitc-2022-005445","volume":"10","author":"BI Rini","year":"2022","unstructured":"Rini\u00a0BI, Signoretti\u00a0S, Choueiri\u00a0TK et\u00a0al (2022) Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advance sarcomatoid renal cell carcinoma. J\u00a0Immunother Cancer 10:e5445","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2473_CR34","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini\u00a0BI, Plimack\u00a0ER, Stus\u00a0V et\u00a0al (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell.Carcinoma. N\u00a0Engl J Med 380(12):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"12","key":"2473_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer\u00a0RJ, Penkov\u00a0K, Haanen\u00a0J et\u00a0al (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N\u00a0Engl J Med 380(12):1103\u20131115","journal-title":"N Engl J Med"},{"key":"2473_CR36","doi-asserted-by":"publisher","first-page":"1223282","DOI":"10.3389\/fonc.2023.1223282","volume":"13","author":"V Gr\u00fcnwald","year":"2023","unstructured":"Gr\u00fcnwald\u00a0V, Powles\u00a0T, Eto\u00a0M et\u00a0al (2023) Phase\u00a03 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib pus pembrolizumab and sunitinib arms. Front Oncol 13:1223282","journal-title":"Front Oncol"},{"issue":"9","key":"2473_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Powles\u00a0T, Burotto M et\u00a0al CheckMate 9ER Investigators. (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N\u00a0Engl J Med 384(9):829\u2013841","journal-title":"N Engl J Med"},{"key":"2473_CR38","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer\u00a0RJ, Tannir\u00a0NM, McDermott\u00a0DF et\u00a0al (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N\u00a0Engl J Med 378:1277\u20131290","journal-title":"N Engl J Med"},{"issue":"14","key":"2473_CR39","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer\u00a0R, Alekseev\u00a0B, Rha\u00a0SY et\u00a0al (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N\u00a0Engl J Med 384(14):1289\u20131300","journal-title":"N Engl J Med"},{"issue":"2","key":"2473_CR40","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms24021096","volume":"24","author":"M Stellato","year":"2023","unstructured":"Stellato\u00a0M, Buti\u00a0S, Maruzzo\u00a0M et\u00a0al (2023) Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a\u00a0Subgroup Analysis of I\u2011RARE Observational Study (Meet-URO 23a). Int J Mol Sci 24(2):1096\u20131096","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2473_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.20.02365","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott\u00a0DF, Lee\u00a0JL, Ziobro\u00a0M et\u00a0al (2021) Open-Label, Single-Arm, Phase\u00a0II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J\u00a0Clin Oncol 39(9):1029\u20131039","journal-title":"J Clin Oncol"},{"issue":"6","key":"2473_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","volume":"18","author":"NJ Vogelzang","year":"2020","unstructured":"Vogelzang\u00a0NJ, Olsen\u00a0MR, McFarlane\u00a0JJ et\u00a0al (2020) Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase\u00a0IIIb\/IV CheckMate 374 Study. Clin Genitourin Cancer 18(6):461\u2013468.e3","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"2473_CR43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000495366","volume":"42","author":"M Ahrens","year":"2019","unstructured":"Ahrens\u00a0M, Scheich\u00a0S, Hartmann\u00a0A et\u00a0al (2019) Non-Clear Cell Renal Cell Carcinoma\u2014Pathology and Treatment Options. Oncol Res Treat 42(3):128\u2013135","journal-title":"Oncol Res Treat"},{"issue":"1","key":"2473_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00345-018-2355-y","volume":"31","author":"C Lebacle","year":"2018","unstructured":"Lebacle\u00a0C, Pooli\u00a0A, Bessede\u00a0T et\u00a0al (2018) Epidemiology, biology and treatment of sarcomatoid RCC: Current state of the art. World J Urol 31(1):115\u2013123","journal-title":"World J Urol"},{"key":"2473_CR45","unstructured":"Maiti A, Nemati-Shafaee M, Msaouel P et\u00a0al (2017) Phase\u00a02 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer (S1558\u20137673(17)30238-0)"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02473-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:04:19Z","timestamp":1733303059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02473-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2473"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02473-6","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"11 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Ahrens und L.\u00a0Bergmann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}